1.5 CE Credit
Douglas Whiteside, PhD, ABPP /CN
Professor of Rehabilitation Medicine
University of Minnesota, Division of Neuropsychology
Department of Rehabilitation Medicine
William Garmoe, Ph.D., ABPP-CN
Director of Psychology, MedStar National Rehabilitation Network
Board Certified Clinical Neuropsychologist
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), which causes COVID-19 illness, has caused considerable economic and social disruption since December 2019. This disruption has stemmed in large part from the highly contagious transmission and high mortality and morbidity rates associated with this novel coronavirus. Broadly, COVID-19 is associated with a range of symptoms including fever, cough, shortness of breath, and, in severe cases, respiratory failure. The short-term and long-term neurological and psychiatric complications (e.g., stroke/vascular changes; acute respiratory distress syndrome[ARDS]) related to COVID-19 infection and treatment (e.g., Intensive Care Unit treatment) are also associated with cognitive dysfunction. In addition, COVID-19 has been associated with direct effects on the central nervous system as well as the respiratory and cardiac systems. Recently, increasing concern about long-term physical and cognitive symptoms amongst patients with initially less severe COVID-19 symptoms has emerged. This presentation will address the current literature on long-term effects of COVID-19 on cognitive functioning and on strategies for rehabilitation of these difficulties. Data will be presented from two COVID-19 recovery programs.
After the session, participants will be able to:
1. Describe the medical and psychological factors that may contribute to cognitive dysfunction following COVID-19.
2. Explain a model for understanding cognitive dysfunction following COVID-19.
Neuropsychologists and trainees
is a board-certified clinical neuropsychologist and Professor of Rehabilitation Medicine at the University of Minnesota. He is also the Director of Training for the Neuropsychology Division and is currently working on collaborative research examining cognitive sequelae of severe COVID-19 infection. Dr. Whiteside earned his PhD from the University of Nebraska after completing internship at the Ann Arbor VA Medical Center, and he completed postdoctoral training in neuropsychology at the Albuquerque VA Medical Center. Dr. Whiteside is a native Midwesterner, who serves as the Program Director for the Clinical Neuropsychology Residency program. He is actively involved in clinical neuropsychological practice, teaching, research, and community service. His research interests focus primarily on performance validity tests, personality assessment measures in neuropsychological assessment, and long term cognitive and emotional outcome of COVID-19 infection. He is an Associate Editor for The Clinical Neuropsychologist. In addition to his work as Program Director of the postdoctoral fellowship in clinical neuropsychology, Dr. Whiteside has considerable previous experience with training program development, which includes establishing a postdoctoral residency at the University of Iowa, developing a doctoral level neuropsychology concentration, establishing a doctoral level on-campus training clinic, and serving as a member of the Board of Directors for a large multidisciplinary medical practice. He is currently President-Elect for the Association of Postdoctoral Programs in Clinical Neuropsychology (APPCN). In addition to his work as a neuropsychologist, Dr. Whiteside is an avid jazz and classical musician and plays in several bands.
Dr. William Garmoe
is the Director of Psychology for MedStar National Rehabilitation Network (MNRN). MNRN is an integrated rehabilitation system including an acute inpatient rehabilitation hospital and network of care through a large number of specialty programs and outpatient clinics. Dr. Garmoe specializes in assessment and treatment of individuals who have and are experiencing traumatic brain injury, aneurysm, dementia, and other neurologic syndromes. Since onset of the pandemic due to SARS-CoV-2, he has worked with both inpatients and outpatients affected by the virus, and was involved in development of the MedStar COVID-19 Recovery Program. Dr. Garmoe also conducts specialty civil and criminal forensic consultations, and is a consultant to the NFL Disability Plans. Dr. Garmoe is board-certified in clinical neuropsychology (ABPP-CN) and is a Fellow of the National Academy of Neuropsychology (NAN).
He holds appointments as Clinical Associate Professor of Rehabilitation Medicine and Neurology in the Georgetown University Medical School. He is a faculty member in the NRH Neuropsychology Fellowship and the Brain Injury Medicine Fellowship programs. Dr. Garmoe has published research in the areas of self-awareness following brain injury and other topics, and is a contributing author to the Clinical Neuropsychology Study Guide and Board Review. Dr. Garmoe is also involved in the bioethics services at MNRN.
NAN members login and non-members create an account to: